scroll to top
0

Mobile Menu

Header Layout

EBSCO Auth Banner

Let's find your institution. Click here.

Page title

Advanced Search Results For "SARS-CoV-2"

1 - 10 of 270,211 results for
 "SARS-CoV-2"
Results per page:

Guillain-Barrè syndrome following COVID-19 vaccine mRNA-1273: a case report.

Publication Type:Report

Source(s):Acta neurologica Belgica [Acta Neurol Belg] 2022 Oct; Vol. 122 (5), pp. 1369-1371. Date of Electronic Publication: 2021 Nov 12.

View details

Heterologous gam-COVID-vac (sputnik V)/mRNA-1273 (moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysis.

Publication Type:Academic Journal

Source(s):Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [Clin Microbiol Infect] 2022 Oct; Vol. 28 (10), pp. 1382-1388. Date of Electronic Publication: 2022 May 17.

Abstract:Objectives: To compare the homologous prime-boost vaccination scheme of Gam-COVID-Vac (Sputnik V (SpV)) to its heterologous combination with mRNA-1273 (Moderna (Mod)) vaccine.Methods: SARS-CoV-2 anti-spike (S)-receptor binding domain (RBD) IgG concentr...

View details

SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodies.

Publication Type:Academic Journal

Source(s):Transplant immunology [Transpl Immunol] 2022 Oct; Vol. 74, pp. 101670. Date of Electronic Publication: 2022 Jul 11.

Abstract:Background: SARS-CoV-2 vaccination is strongly recommended in kidney transplant recipients (KTR) and dialysis patients. Whether these vaccinations may trigger alloantibodies, is still debated.Methods: In the current study we evaluated the effect of SAR...

View details

Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and SARS-CoV-2-Related Hospitalizations: A Statewide Report From the Minnesota Electronic Health Record Consortium.

Publication Type:Academic Journal

Source(s):Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2022 Sep 14; Vol. 75 (5), pp. 890-892.

Abstract:Using vaccine data combined with electronic health records, we report that mRNA boosters provide greater protection than a 2-dose regimen against SARS-CoV-2 infection and related hospitalizations. The benefit of a booster was more evident in the elderl...

View details

Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination.

Publication Type:Academic Journal

Source(s):American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2022 Sep; Vol. 22 (9), pp. 2254-2260. Date of Electronic Publication: 2022 May 03.

Abstract:Heterologous vaccination ("mixing platforms") for the third (D3) dose of SARS-CoV-2 vaccine is a potential strategy to improve antibody responses in solid organ transplant recipients (SOTRs), but data are mixed regarding potential differential immunoge...

View details

Lymphohistiocytic Myocarditis Possibly Due to Moderna mRNA-1273 Vaccine.

Publication Type:Academic Journal

Source(s):American journal of clinical pathology [Am J Clin Pathol] 2022 Aug 04; Vol. 158 (2), pp. 167-172.

Abstract:Objectives: Despite the clear benefits of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in mitigating the impact of the coronavirus disease 2019 pandemic, there are emerging reports of postvaccination myocarditis, the majorit...

View details

Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination.

Publication Type:Editorial & Opinion

Source(s):The New England journal of medicine [N Engl J Med] 2022 Sep 29; Vol. 387 (13), pp. 1234-1236. Date of Electronic Publication: 2022 Sep 09.

View details

Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens.

Publication Type:Academic Journal

Source(s):Nature communications [Nat Commun] 2022 Aug 11; Vol. 13 (1), pp. 4710. Date of Electronic Publication: 2022 Aug 11.

Abstract:Comparative analyses of the immunogenicity and reactogenicity of homologous and heterologous SARS-CoV-2 vaccine-regimens will inform optimized vaccine strategies. Here we analyze the humoral and cellular immune response following heterologous and homol...

View details

Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine.

Publication Type:Academic Journal

Source(s):American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2022 Aug; Vol. 22 (8), pp. 2089-2093. Date of Electronic Publication: 2022 Mar 21.

Abstract:The SARS-CoV-2 virus Omicron variant has now supplanted wild-type virus as the dominant circulating strain globally. Three doses of mRNA COVID-19 vaccine are recommended for transplant recipients as their primary vaccine series. However, the immunogeni...

View details

mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2.

Publication Type:Academic Journal

Source(s):Med (New York, N.Y.) [Med (N Y)] 2022 May 13; Vol. 3 (5), pp. 309-324.e6. Date of Electronic Publication: 2022 Apr 15.

Abstract:Background: Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019, viral variants with greater transmissibility or immune-evasion properties have arisen, which could jeopardize recently deployed vaccine- and antibo...

View details

banner_970x250 (970x250)

sponsored